174 related articles for article (PubMed ID: 22837653)
1. Pharmacophore and molecular docking guided 3D-QSAR study of bacterial enoyl-ACP reductase (FabI) Inhibitors.
Lu X; Lv M; Huang K; Ding K; You Q
Int J Mol Sci; 2012; 13(6):6620-6638. PubMed ID: 22837653
[TBL] [Abstract][Full Text] [Related]
2. The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
Yogiara ; Mordukhova EA; Kim D; Kim WG; Hwang JK; Pan JG
Bioorg Med Chem Lett; 2020 Dec; 30(24):127651. PubMed ID: 33130290
[TBL] [Abstract][Full Text] [Related]
3. FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.
Rana P; Ghouse SM; Akunuri R; Madhavi YV; Chopra S; Nanduri S
Eur J Med Chem; 2020 Dec; 208():112757. PubMed ID: 32883635
[TBL] [Abstract][Full Text] [Related]
4. Ligand- and Structure-Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence.
Kronenberger T; de Oliveira Fernades P; Drumond Franco I; Poso A; Gonçalves Maltarollo V
ChemMedChem; 2019 Dec; 14(23):1995-2004. PubMed ID: 31670463
[TBL] [Abstract][Full Text] [Related]
5. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR studies on triclosan derivatives as Plasmodium falciparum enoyl acyl carrier reductase inhibitors.
Shah P; Siddiqi MI
SAR QSAR Environ Res; 2010 Jul; 21(5-6):527-45. PubMed ID: 20818586
[TBL] [Abstract][Full Text] [Related]
7. Structure of acyl carrier protein bound to FabI, the FASII enoyl reductase from Escherichia coli.
Rafi S; Novichenok P; Kolappan S; Stratton CF; Rawat R; Kisker C; Simmerling C; Tonge PJ
J Biol Chem; 2006 Dec; 281(51):39285-39293. PubMed ID: 17012233
[TBL] [Abstract][Full Text] [Related]
8. Role of inhibitor aliphatic chain in the thermodynamics of inhibitor binding to Escherichia coli enoyl-ACP reductase and the Phe203Leu mutant: a proposed mechanism for drug resistance.
Protasevich II; Brouillette CG; Snow ME; Dunham S; Rubin JR; Gogliotti R; Siegel K
Biochemistry; 2004 Oct; 43(42):13380-9. PubMed ID: 15491144
[TBL] [Abstract][Full Text] [Related]
9. Insight through molecular mechanics Poisson-Boltzmann surface area calculations into the binding affinity of triclosan and three analogues for FabI, the E. coli enoyl reductase.
Rafi SB; Cui G; Song K; Cheng X; Tonge PJ; Simmerling C
J Med Chem; 2006 Jul; 49(15):4574-80. PubMed ID: 16854062
[TBL] [Abstract][Full Text] [Related]
10. Escherichia coli enoyl-acyl carrier protein reductase (FabI) supports efficient operation of a functional reversal of β-oxidation cycle.
Vick JE; Clomburg JM; Blankschien MD; Chou A; Kim S; Gonzalez R
Appl Environ Microbiol; 2015 Feb; 81(4):1406-16. PubMed ID: 25527535
[TBL] [Abstract][Full Text] [Related]
11. Discovery of new potential hits of Plasmodium falciparum enoyl-ACP reductase through ligand- and structure-based drug design approaches.
Neves BJ; Bueno RV; Braga RC; Andrade CH
Bioorg Med Chem Lett; 2013 Apr; 23(8):2436-41. PubMed ID: 23499236
[TBL] [Abstract][Full Text] [Related]
12. Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI).
Sampson PB; Picard C; Handerson S; McGrath TE; Domagala M; Leeson A; Romanov V; Awrey DE; Thambipillai D; Bardouniotis E; Kaplan N; Berman JM; Pauls HW
Bioorg Med Chem Lett; 2009 Sep; 19(18):5355-8. PubMed ID: 19682901
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors.
Vaidya M; Weigt M; Wiese M
Eur J Med Chem; 2009 Oct; 44(10):4070-82. PubMed ID: 19515462
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
Seefeld MA; Miller WH; Newlander KA; Burgess WJ; Payne DJ; Rittenhouse SF; Moore TD; DeWolf WE; Keller PM; Qiu X; Janson CA; Vaidya K; Fosberry AP; Smyth MG; Jaworski DD; Slater-Radosti C; Huffman WF
Bioorg Med Chem Lett; 2001 Sep; 11(17):2241-4. PubMed ID: 11527706
[TBL] [Abstract][Full Text] [Related]
15. Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex.
Chang A; Schiebel J; Yu W; Bommineni GR; Pan P; Baxter MV; Khanna A; Sotriffer CA; Kisker C; Tonge PJ
Biochemistry; 2013 Jun; 52(24):4217-28. PubMed ID: 23697754
[TBL] [Abstract][Full Text] [Related]
16. Cephalochromin, a FabI-directed antibacterial of microbial origin.
Zheng CJ; Sohn MJ; Lee S; Hong YS; Kwak JH; Kim WG
Biochem Biophys Res Commun; 2007 Nov; 362(4):1107-12. PubMed ID: 17825252
[TBL] [Abstract][Full Text] [Related]
17. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli.
Heath RJ; Rock CO
J Biol Chem; 1995 Nov; 270(44):26538-42. PubMed ID: 7592873
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore-based alignment.
Lu XY; Chen YD; You QD
Chem Biol Drug Des; 2010 Feb; 75(2):195-203. PubMed ID: 20028393
[TBL] [Abstract][Full Text] [Related]
19. Methyl-branched fatty acids, inhibitors of enoyl-ACP reductase with antibacterial activity from Streptomyces sp. A251.
Zheng CJ; Sohn MJ; Chi SW; Kim WG
J Microbiol Biotechnol; 2010 May; 20(5):875-80. PubMed ID: 20519910
[TBL] [Abstract][Full Text] [Related]
20. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
Heerding DA; Chan G; DeWolf WE; Fosberry AP; Janson CA; Jaworski DD; McManus E; Miller WH; Moore TD; Payne DJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Smith W; Takata DT; Vaidya KS; Yuan CC; Huffman WF
Bioorg Med Chem Lett; 2001 Aug; 11(16):2061-5. PubMed ID: 11514139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
